SpinaFX Appoints John Soloninka as COO

Minimally invasive image-guided therapy start-up SpinaFX appointed of John Soloninka as COO.
 
John is a healthtech entrepreneur and ex IBM and Price Waterhouse healthcare system strategist bringing extensive industry, commercialization, regulatory and financing expertise to SpinaFX’s growing team.
 
John previously served as CEO and co-founder of a $28M public/private venture debt fund, overseeing a syndicated $86M (CDN) investment in 36 early-stage healthtech companies including Synaptive Medical, CONAVI, SPARTAN, and Profound Medical. Among his several start-ups, John co-founded an AI-based oncology management company, ultimately acquired by Varian Medical Systems, and co-founded and led product development and operations for a cloud-based medical imaging company sold to Merge Technologies of Milwaukee which was ultimately purchased by IBM.
 
Designated by the Industry Canada as a “Canadian Investment Champion” John pursued healthcare commercialization initiatives throughout Asia, Europe the US, and Middle East. John’s appointments to research and commercialization advisory posts with the Rotman Research Institute and the Ontario Brain Institute, and as an expert witness to Canada’s Standing Parliamentary Committee on Healthcare, reflect his industry knowledge and stature in this space. Formerly a Professional Engineer, John has a BSc in Engineering Physics from Queen’s University and an MBA with Distinction from the Imperial College Business School, London UK.
 
Commenting on his appointment, John said: “I am delighted to join the SpinaFX team. Triojection™ has great potential to provide patients with an earlier, simpler back pain procedure, surgeons with a quicker, less-invasive treatment option, and payers with a lower cost per case. Dr. Kieran Murphy, SpinaFX’s chief medical officer, has world-leading expertise in minimally invasive, image-guided technology innovation. Jeff Cambra, SpinaFX’s CEO, has been at the forefront of marketing transformative medical technologies for the global interventional spine market with Medtronic. My background complements these experts and together provides a great foundation to grow SpinaFX.”
 
Jeff Cambra commented: “John brings an incredible combination of personal characteristics, skills, relevant expertise and strategic insights. His professional training, discipline, and entrepreneurial approach to business is invaluable to SpinaFX’s early-stage commercialization and growth. I am extremely pleased John has chosen to join us.”
 
Igor Keselman, SpinaFX’s Executive Chair, said “John is a seasoned, hands-on healthtech leader. John’s past advisory roles to leading institutions reflects his commitment to and respect within our industry. John is an important addition to our team”.